Prestige BioPharma Limited

KSE:950210.KS

16860 (KRW) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

2023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q4
Operating Activities:
Net Income -13,055.824-1,447.792-13,027.978-17,032.206-15,333.113-22,138.633-19,014.85753,627.837-101,309.789-85,958.054-14,011.632-10,170.6622,581.8-9,707.58135.516-400.672-6,788.282
Depreciation & Amortization 04,478.7923,841.7923,414.9283,415.6473,263.9923,146.9311,800.1861,181.812955.456964.046782.583539.794000520.934
Deferred Income Tax 000000000000-11,445.5730000
Stock Based Compensation 000000000000368.6880000
Change In Working Capital 000000000000-1,320.585000-9,884.741
Accounts Receivables 000000000000931.8840000
Change In Inventory 00000000000000000
Change In Accounts Payables 0000000000001,014.3170000
Other Working Capital 000000000000-3,264.5420000
Other Non Cash Items -8,570.737-4,928.479-2,336.0911,339.294-12,875.9116,809.893-2,221.323-70,754.63689,136.36760,280.4091,025.35513,918.938398.52410,701.755-9,908.8732,610.8034,473.716
Operating Cash Flow -13,420.76-10,855.063-11,522.276-12,277.984-24,793.376-2,064.748-18,089.249-15,326.613-10,991.61-25,677.645-12,986.2773,748.276-8,877.352994.175-9,773.3572,210.131-11,678.373
Investing Activities:
Investments In Property Plant And Equipment -6,723.277-6,925.631-6,237.368-8,074.221-8,911.821-23,113.946-19,635.718-13,955.197-14,184.835-10,333.325-22,455.856-21,138.619-3,114.48-5,138.716-3,291.007-6,567.233-727.701
Acquisitions Net 0-0.469-18.17369.943-72.984-35.558316.74239,830.4029,671.7716,816.320000000
Purchases Of Investments 00-0-69.943-133,690.599000-412.086-20,714.171-2,040.97-2,072.18900000
Sales Maturities Of Investments 23,026.164301.267134,822.1351,722.688133,690.599000-9,671.7700000000
Other Investing Activites -15.0321.1672,733.766-2,591.889-124,765.105958.638499.733274.56215,337.924-76,023.128-23,975.765-14,051.688-2,963.281-757.6171,034.766-114.792,205.041
Investing Cash Flow 16,729.555-6,603.667131,300.359-8,943.422-133,749.91-22,190.866-18,819.24326,149.767741.003-107,070.624-45,459.552-32,896.077-6,077.761-5,896.333-2,256.241-6,682.0231,477.34
Financing Activities:
Debt Repayment 00000000000000000
Common Stock Issued -4.908874.36436.46600000000014,576.4490000
Common Stock Repurchased 00000000000000000
Dividends Paid 00000000000000000
Other Financing Activities -501.2390-480.7434,741.61110,577.40544,302.72-429.149-391.584-431.847-409.616-482.487-264.733-10,782.12452,293.531-82.328-99.634-1,557.858
Financing Cash Flow -504.017119.955-3,212.0342,128.92510,511.43644,031.431-697.596-661.893-479.438-436.287-448.24-3,139.5413,365.892451,857.483-97.296-609.526-1,557.858
Other Information:
Effect Of Forex Changes On Cash 1,678.684-2,030.1022,134.535-1,174.3941,835.549-3,164.3578,298.638-81.553-718.491-43.579-1,608.948-805.5498,043.334-8,670.29159.605289.80982.178
Net Change In Cash 5,674.826-22,669.0221,617.667-20,266.875-146,697.07211,605.821-27,096.57410,079.708-3,483.49-128,764.297-55,174.031-33,092.891-3,453.604437,513.465-13,403.268-4,791.609-11,905.897
Cash At End Of Period 210,483.42241,389.92564,058.947104,578.895125,909.523272,606.595261,000.774288,097.348249,569.236253,052.726381,817.023436,991.054461,375.603464,829.20727,315.74240,719.0145,783.636